Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/129822
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Preclinical study of the pharmacokinetics of p75ECD-Fc, a novel human recombinant protein for treatment of Alzheimer’s disease, in Sprague Dawley rats
Author: Kelliny, S.
Lam, H.Y.
Parikh, A.
Wang, Y.J.
Bobrovskaya, L.
Upton, R.
Zhou, X.F.
Citation: Current Drug Metabolism, 2020; 21(3):235-244
Publisher: Bentham Science
Issue Date: 2020
ISSN: 1389-2002
1875-5453
Statement of
Responsibility: 
Sally Kelliny, Ho Yin Lam, Ankit Parikh, Yan-Jiang Wang, Larisa Bobrovskaya, Richard Upton, Xin-Fu Zhou
Abstract: Background: p75ECD-Fc is a recombinant human protein that has recently been developed as a novel therapy for Alzheimer’s disease. Current studies showed that it is able to alleviate Alzheimer’s disease pathologies in animal models of dementia. Thus, knowledge about the pharmacokinetic behavior and tissue distribution of this novel protein is crucial in order to better understand its pharmacodynamics and more importantly for its clinical development. Methods: The aim of this study is to characterize the pharmacokinetics of p75ECD-Fc after single intravenous and subcutaneous injection of 3mg/kg in Sprague Dawley rats. We calculated the bioavailability of the SC route and studied the distribution of that protein in different tissues, cerebrospinal fluid and urine using ELISA and immunofluorescence techniques. In-vitro stability of the drug was also assessed. Data obtained were analyzed with Non-compartmental pharmacokinetic method using R. Results: Results showed that the bioavailability of SC route was 66.15%. Half-life time was 7.5 ± 1.7 and 6.2 ± 2.4 days for IV and SC injection, respectively. Tissue distribution of p75ECD-Fc was modest with the ability to penetrate the blood brain barrier. It showed high in vitro stability in human plasma. Conclusion: These acceptable pharmacokinetic properties of p75ECD-Fc present it as a potential candidate for clinical development for the treatment of Alzheimer’s disease.
Keywords: Alzheimer's disease; pharmacokinetics; p75ECD-Fc; amyloid-β; p75 neurotrophin receptor; non-compartmental analysis
Description: Full Text Unavailable.
Rights: Copyright Status Unknown
DOI: 10.2174/1389200221666200502015203
Grant ID: http://purl.org/au-research/grants/nhmrc/1020567
http://purl.org/au-research/grants/nhmrc/1021409
Published version: http://dx.doi.org/10.2174/1389200221666200502015203
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.